openPR Logo
Press release

Lawsuit filed for Investors in shares of Revance Therapeutics, Inc. (NASDAQ: RVNC)

01-07-2022 07:23 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Shareholders Foundation

A lawsuit was filed on behalf of investors in Revance Therapeutics, Inc. (NASDAQ: RVNC) shares.

A lawsuit was filed on behalf of investors in Revance Therapeutics, Inc. (NASDAQ: RVNC) shares.

An investor in shares of Revance Therapeutics, Inc. (NASDAQ: RVNC) filed a lawsuit over alleged Securities Laws violations by Revance Therapeutics, Inc.

Investors who purchased shares of Revance Therapeutics, Inc. (NASDAQ: RVNC) have certain options and for certain investors are short and strict deadlines running. Deadline: February 8, 2022. NASDAQ: RVNC investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

Newark, CA based Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally.

On August 5, 2021, Revance Therapeutics, Inc. reported its second quarter financial results. In the announcement Revance Therapeutics, Inc. said that “Consistent with the company’s previous disclosure on the status of the pre-approval inspection, the FDA initiated the inspection of the company’s manufacturing facility in June 2021. Revance continues to anticipate receiving approval for DaxibotulinumtoxinA for Injection in 2021 and is actively building inventory and preparing for commercial launch.”

On October 12, 2021, Revance Therapeutics, Inc. issued a statement saying that it “continues to anticipate FDA approval of daxibotulinumtoxinA for injection for the treatment of glabellar lines in 2021”.

Then , on October 15, 2021, Revance Therapeutics, Inc. disclosed that the FDA could not approve the Biologics License Application (BLA) for DaxibotulinumtoxinA for Injection in its present form, citing deficiencies related to an inspection of Revance's manufacturing facility.

Shares of Revance Therapeutics, Inc. (NASDAQ: RVNC) declined from $30.00 per share on September 27, 2021, to $13.01 per share on October 18, 2021.

The plaintiff claims that between November 25, 2019 and October 11, 2021, the Defendants made false and/or misleading statements and/or failed to disclose that quality control deficiencies existed at the Company’s manufacturing facility for DAXI, that the foregoing deficiencies decreased the likelihood that the FDA would approve the DAXI BLA in its current form, that accordingly, it was unlikely that the DAXI BLA would obtain FDA approval within the timeframe the Company had represented to investors, and that as a result, the Company’s public statements were materially false and misleading at all relevant times.

Those who purchased shares of Revance Therapeutics, Inc. (NASDAQ: RVNC) have certain options and should contact the Shareholders Foundation.

Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Lawsuit filed for Investors in shares of Revance Therapeutics, Inc. (NASDAQ: RVNC) here

News-ID: 2521010 • Views:

More Releases from Shareholders Foundation

ALERT: Lawsuit filed for Investors who SOLD shares of Sina Corporation (formerly NASDAQ: SINA)
ALERT: Lawsuit filed for Investors who SOLD shares of Sina Corporation (formerly …
An investor, who sold shares of Sina Corporation (formerly NASDAQ: SINA) in the merger between Seina Corporation and TuSimple Holdings, Inc, filed a lawsuit over alleged violations of Federal Securities Laws by Sina Corporation (formerly NASDAQ: SINA in connection with certain allegedly false and misleading statements made. If you sold a significant amount of shares of Sina Corporation (formerly NASDAQ: SINA) between October 13, 2020 and March 22, 2021, you have
Lawsuit Alert: Investors who lost money with shares of Fluor Corporation (NYSE: FLR) should contact the Shareholders Foundation
Lawsuit Alert: Investors who lost money with shares of Fluor Corporation (NYSE: …
An investor, who purchased shares of Fluor Corporation (NYSE: FLR), filed a lawsuit alleged violations of Federal Securities Laws by Fluor Corporation in connection with certain allegedly false and misleading statements. Investors who purchased shares of Fluor Corporation (NYSE: FLR) have certain options and for certain investors are short and strict deadlines running. Deadline: November 14, 2025. NYSE: FLR investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779
Investigation announced for Long-Term Investors in shares of Sable Offshore Corp. (NYSE: SOC)
Investigation announced for Long-Term Investors in shares of Sable Offshore Corp …
An investigation was announced for long-term investors in shares of Sable Offshore Corp. (NYSE: SOC) concerning potential breaches of fiduciary duties by certain directors of Sable Offshore Corp. Investors who are current long term investors in Sable Offshore Corp. (NYSE: SOC) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for current long term investors in
Lawsuit filed for Investors who lost money with shares of Lantheus Holdings, Inc. (NASDAQ: LNTH)
Lawsuit filed for Investors who lost money with shares of Lantheus Holdings, Inc …
An investor, who purchased shares of Lantheus Holdings, Inc. (NASDAQ: LNTH), filed a lawsuit over alleged violations of Federal Securities Laws by Lantheus Holdings, Inc. in connection with certain allegedly false and misleading statements. Investors who purchased shares of Lantheus Holdings, Inc. (NASDAQ: LNTH) have certain options and for certain investors are short and strict deadlines running. Deadline: November 10, 2025. NASDAQ: LNTH investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com

All 5 Releases


More Releases for Revance

Botulinum Toxin Injections Market Is Booming Worldwide | Allergan, Ipsen, Revanc …
HTF MI just released the Global Botulinum Toxin Injections Market Study, a comprehensive analysis of the market that spans more than 143+ pages and describes the product and industry scope as well as the market prognosis and status for 2025-2033. The marketization process is being accelerated by the market study's segmentation by important regions. The market is currently expanding its reach. Major Giants in Botulinum Toxin Injections Market are: Allergan (US), Ipsen
Aesthetic Service Market Is Booming Worldwide | Allergan, Galderma, Merz Pharmac …
The Global Aesthetic Service Market is estimated to be valued at USD 21.94 Bn in 2025 and is expected to reach USD 36.40 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 7.5% from 2025 to 2032. The qualitative latest Research report (2025-2032) on the Aesthetic Service Market by Coherent Market Insights Provides a deep dive into key market trends, drivers, challenges, and the competitive landscape. It analyzes
Lip Augmentation Market Trends and Forecast | Key Players: Revance Therapeutics, …
Lip Augmentation Market Overview The global lip augmentation market is projected to grow from USD 3.1 billion in 2024 to USD 6.1 billion by 2033, exhibiting a CAGR of 7.78% during the forecast period. Coherent Market Insights is pleased to release its latest Lip Augmentation Market research report, offering an in-depth analysis of the U.S. Lip Augmentation Market Landscape from 2025 to 2032. This report delivers reliable projections across national and regional
Facial Injectable Market Is Booming So Rapidly | Evolus, Hugel, Revance
The Global Facial Injectable Market Size is estimated at $12.9 Billion in 2025 and is forecast to register an annual growth rate (CAGR) of 10.1% to reach $30.7 Billion by 2034. The latest study released on the Global Facial Injectable Market by USD Analytics Market evaluates market size, trend, and forecast to 2034. The Facial Injectable market study covers significant research data and proofs to be a handy resource document for
Investigation announced for Investors in Revance Therapeutics, Inc. (NASDAQ: RVN …
An investigation was announced for long-term investors in shares of Revance Therapeutics, Inc. (NASDAQ: RVNC) concerning potential breaches of fiduciary duties by certain directors and officers of Revance Therapeutics, Inc. Investors who are current long term investors in Revance Therapeutics, Inc. (NASDAQ: RVNC) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for current long term
Investigation announced for Investors in shares of Revance Therapeutics, Inc. (N …
An investigation was announced over potential securities laws violations by Revance Therapeutics, Inc. in connection with certain financial statements. Investors who purchased shares of Revance Therapeutics, Inc. (NASDAQ: RVNC), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm focuses on whether a series of statements by Revance Therapeutics, Inc. regarding its business, its prospects and its operations were